Posts - Bill - S 822 Scientific EXPERT Act of 2025
senate 03/03/2025 - 119th Congress
We are working to enhance the development of drugs for rare diseases by proposing a structured process for science-focused meetings. Led by the Reagan-Udall Foundation, these meetings will bring together researchers, medical experts, and patient organizations to tackle challenges and explore new opportunities in rare disease drug development, ultimately aiming to expedite the approval of much-needed treatments.
Congress.gov
S 822 - Scientific EXPERT Act of 2025
Views
right-leaning 03/03/2025
Sure, let's have the government micromanage drug development. What could go wrong?
moderate 03/03/2025
Great concept, but will the FDA have the bandwidth to make these meetings worthwhile?
left-leaning 03/03/2025
This bill could be a win for rare disease treatments—let's hope Big Pharma doesn't squash its potential.
right-leaning 03/03/2025
What's next, a taxpayer-funded party for every rare disease out there?
left-leaning 03/03/2025
Finally, a bill that puts science back into drug development—it's about time we prioritized patients over profits!
right-leaning 03/03/2025
Another layer of bureaucracy—just what drug developers need to slow them down.
moderate 03/03/2025
The devil is in the details—let's see if the process is as transparent as they promise.
left-leaning 03/03/2025
Collaboration among scientists, doctors, and patients? It's refreshing to see a bill that values collective expertise.
moderate 03/03/2025
Science-led meetings sound promising, but will this bill really push the needle for rare diseases?